Retraction notice to "The retinoic acid receptor/CaMKII interaction: Pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells" [Blood Cells Mol. Dis. 39 (2007) 307-315] (DOI:10.1016/j.bcmd.2007.05.009);The retinoic acid receptor/CaMKII interaction: Pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells

Blood Cells, Molecules, and Diseases

Volumn 39, Issue 3, 2007, Pages 307-315

  Si, Jutong ^a   Mueller, LeMoyne ^a   Schuler, Aaron ^a   Simon, Julian ^a   Collins, Steven J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Ca++ calmodulin dependent protein kinases; HL 60 cell line; KN 62; Myeloid leukemia cell differentiation; Retinoic acid receptors

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; AS 04; CALMODULIN; CALMODULIN DEPENDENT PROTEIN KINASE; CALMODULIN INHIBITOR; PROTEIN KINASE; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; ENZYME INHIBITION; MOUSE; MYELOID LEUKEMIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

MUS;

EID: 34748867120     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.05.011     Document Type: Erratum

References (22)

1. Brown P., Meshinchi S., Levis M., et al. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood 104 (2004) 1841-1849
2. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev., Drug Discov. 1 (2002) 287-299
3. Tallman M.S., Nabhan C., Feusner J.H., and Rowe J.M. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99 (2002) 759-767
4. Hook S.S., and Means A.R. Ca(2+)/CaM-dependent kinases: from activation to function. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 471-505
5. Anderson K.A., and Means A.R. Defective signaling in a subpopulation of CD4(+) T cells in the absence of Ca(2+)/calmodulin-dependent protein kinase IV. Mol. Cell. Biol. 22 (2002) 23-29
6. Nghiem P., Ollick T., Gardner P., and Schulman H. Interleukin-2 transcriptional block by multifunctional Ca2+/calmodulin kinase. Nature 371 (1994) 347-350
7. Gaudilliere B., Konishi Y., de la Iglesia N., et al. A CaMKII-NeuroD signaling pathway specifies dendritic morphogenesis. Neuron 41 (2004) 229-241
8. Lisman J., Schulman H., and Cline H. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat. Rev., Neurosci. 3 (2002) 175-190
9. Si J., and Collins S.J. IL-3-induced enhancement of retinoic acid receptor activity is mediated through Stat5, which physically associates with retinoic acid receptors in an IL-3-dependent manner. Blood 100 (2002) 4401-4409
10. Si J., Mueller L., and Collins S.J. CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. J. Clin. Invest. 117 (2007) 1412-1421
11. Schuler A.D., Si J., Mueller L., et al. KN-62 analogues as potent differentiating agents of HL-60 cells. Leuk. Res. 31 (2007) 683-689
12. Collins S., Robertson K., and Mueller L. Retinoic acid induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol. Cell. Biol. 10 (1990) 2154-2163
13. Johnson B., Chandraratna R., Heyman R., Allegretto E., Mueller L., and Collins S. RXR agonist-induced activation of dominant negative RXR-RAR*403 heterodimers is developmentally regulated during myeloid differentiation. Mol. Cell. Biol. 19 (1999) 3372-3382
14. Tokumitsu H., Chijiwa T., Hagiwara M., et al. KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 265 (1990) 4315-4320
15. Sumi M., Kiuchi K., Ishikawa T., et al. The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem. Biophys. Res. Commun. 181 (1991) 968-975
16. Planas-Silva M.D., and Means A.R. Expression of a constitutive form of calcium/calmodulin dependent protein kinase II leads to arrest of the cell cycle in G2. EMBO J. 11 (1992) 507-517
17. Heery D.M., Kalkhoven E., Hoare S., and Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 (1997) 733-736
18. Glass C.K., and Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14 (2000) 121-141
19. White R.R., Kwon Y.G., Taing M., et al. Definition of optimal substrate recognition motifs of Ca2+-calmodulin-dependent protein kinases IV and II reveals shared and distinctive features. J. Biol. Chem. 273 (1998) 3166-3172
20. Robertson K., Emami B., and Collins S. Retinoic acid-resistant HL-60R cells harbor a point mutation in the RA receptor ligand binding domain that confers dominant negative activity. Blood 80 (1992) 1885-1889
21. Park D.J., Chumakov A.M., Vuong P.T., et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J. Clin. Invest. 103 (1999) 1399-1408
22. Lanotte M., Martin-Thouvenin V., Najman S., et al. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77 (1991) 1080-1086